Viral Vectors And Plasmid DNA Manufacturing Market Size, Share & Trends Analysis Report By Vector Type, By Workflow, By Application, By End Use, By Disease, By Product Type, By Region And Segment Forecasts From 2022 To 2030

Report ID: MN17620365  |  Published: November 2022  |  No of Pages: 347
Format: Electronic (PDF)  |  Industry: Biotechnology

The global viral vectors and plasmid DNA manufacturing market size is forecasted to reach USD 11.2 billion by 2030, registering a CAGR of 14.7% from 2022 to 2030. A viral vector is an apparatus used to deliver genetic material in cells. A virus has an exceptional mechanism to transport the DNA in the cells that they infect. Specific viral vectors including adenovirus, retrovirus, simplex herpes virus, lentivirus, and others can be deployed to deliver genetic material onto the genomic cell composition.

The growth of the market is driven by the increase in global incidences of cancer and the increasing accessibility of sophisticated healthcare amenities. Additionally, gene therapy treatments including therapeutic gene vaccines, suicide gene therapy, anti-angiogenesis, and oncolytic virotherapy have been developed to cure different types of tumors. Such developments are opportunistic for market growth during the upcoming years.

The Adeno-associated Virus (AAV) vector type dominated the global market with a revenue share of over 18.9% in 2021. This is attributable to the development of orthopedic and ocular gene therapy treatments displaying enhanced efficiency and efficacy. In recent times, the adoption of AAV is considerably increasing across multiple therapeutic areas, thereby creating growth opportunities for the market demand.

The downstream processing workflow held the largest market share in 2021. The surging market demand for viral vectors owing to their escalating emergence in therapeutics has steered the need to optimize downstream processing. The methods for small-scale virus development typically include measures that are challenging to scale up. Resultantly, various commercial scalable processes are examined and optimized for ensuring the virus quantity along with the quality. These factors are boosting segmental growth.

The vaccinology application accrued the largest revenue share in the global market in 2021. The recent outbreak of COVID-19 impelled the deployment of viral vectors in vaccine research & development. The non-replicating viral vectors are deployed in the viral vector vaccines for COVID-19. The scientific community repurposed the existing methodologies catering to the need for developing an appropriate vaccine. Such advancements encourage product demand.

The Asia Pacific region is anticipated to expand at the fastest growth rate owing to the uptrend in patient influx, paired with the increase in research & development activities in viral vectors. Furthermore, individuals from western nations travel to various countries in Asia for stem cell therapy due to the less restrictive legal framework in the region. Moreover, Asia Pacific offers comparatively low-priced manufacturing and operating units for research activities. These factors play a significant role in supplementing the product demand in the market. 

The global market is majorly fragmented with the existence of numerous well-established and small & medium-sized emerging market players. Several players opt for various growth strategies including mergers, acquisitions, and geographical expansion in economically favorable and emerging economies. For Instance, Cobra Biologics widened its facilities of manufacturing in the U.S and Europe in January 2021. It comprises the 4X expansion in the HQ DNA facility and the commencement of new manufacturing facilities in the European region. This aided in enhancing the company’s market position.

Viral Vectors and Plasmid DNA Manufacturing Market Report Key Takeaways

  • By vector type, the Adeno-associated Virus (AAV) vector type dominated the global market with a revenue share of over 18.9% in 2021. AAVs are witnessing immense market demand as their adoption in clinical trials is accelerating owing to the highest accuracy levels they offer in transferring the gene.
  • By disease, the cancer segment is expected to depict a lucrative growth rate during the forecast period. Viral vector clinical trials that were conducted for various cancer indications signified positive outcomes. Further, the efficacy can be enhanced by dose optimization and vector engineering.
  • North America held the largest market share in the global market in 2021, owing to a robust regulatory framework for encouraging the development of gene therapy and the high therapy cost in the U.S.


Viral Vectors and Plasmid DNA Manufacturing Market Segments

  • Viral Vectors and Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
    • Adenovirus
    • Retrovirus
    • Adeno-Associated Virus (AAV)
    • Lentivirus
    • Plasmids
    • Others
  • Viral Vectors and Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
    • Upstream Manufacturing
      • Vector Amplification & Expansion
      • Vector Recovery/Harvesting
    • Downstream Manufacturing
      • Purification
      • Fill Finish
  • Viral Vectors and Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
    • Antisense & RNAi Therapy
    • Gene Therapy
    • Cell Therapy
    • Vaccinology
    • Research Applications
  • Viral Vectors and Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
    • Pharmaceutical and Biopharmaceutical Companies
    • Research Institutes
  • Viral Vectors and Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
    • Cancer
    • Genetic Disorders
    • Infectious Diseases
    • Others
  • Viral Vectors and Plasmid DNA Manufacturing Product Type Outlook (Revenue, USD Million, 2018 - 2030)
    • Plasmid DNA
    • Viral Vector
    • Non-Viral Vector
  • Viral Vectors and Plasmid DNA Manufacturing Regional Outlook (Revenue, USD Million, 2018 - 2030)
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • U.K.
      • France
      • Spain
      • Italy
    • Asia Pacific
      • Japan
      • China
      • India
      • South Korea
      • Australia
    • Latin America
      • Brazil
      • Mexico
      • Argentina
    • Middle East and Africa (MEA)
      • South Africa
      • Saudi Arabia
      • UAE
  • List of Key Players in Viral Vectors and Plasmid DNA Manufacturing Market
    • Merck KGaA
    • Lonza
    • FUJIFILM Diosynth Biotechnologies
    • Thermo Fisher Scientific
    • Cobra Biologics
    • Catalent Inc.
    • Wuxi Biologics
    • Takara Bio Inc.
    • Waisman Biomanufacturing
    • Genezen laboratories
    • Batavia Biosciences
    • Miltenyi Biotec GmbH
    • SIRION Biotech GmbH
    • Virovek Incorporation
    • BioNTech IMFS GmbH
    • Audentes Therapeutics
    • BioMarin Pharmaceutical
    • RegenxBio, Inc.
What questions do you have? Get quick response from our industry experts. Request More information
Key questions answered in the report include
key questions
We also offers customization on reports based on specific client requirement.
Request for Customization

Choose License Type

Research Assistance

Ryan Manuel
Ryan Manuel

Research Support Specialist, USA

  1. Phone: +1-408-610-2300
  2. Toll Free: +1-866-831-4085
  3. Email: [email protected]
Connect With Expert
  • World's largest premium report database
  • Transparent pre & post sale customer engagement model
  • Unparalleled flexibility in terms of rendering services
  • Safe & secure web experience
  • 24*5 Research support service

Get a Free Sample

FREE sample contains market data points, ranging from trend analyses to market estimates & forecasts. See for yourself...